Literature DB >> 17936719

Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation.

S Moein Moghimi1, Majid Moghimi.   

Abstract

An efficient strategy for enhancing the lymph node deposition of rapidly drained liposomes from the interstitial injection site is described. Subcutaneously injected small-sized immuno-poly(ethyleneglycol)-liposomes (immuno-PEG-liposomes), containing 10 mol% mPEG350-phospholipid and 1 mol% PEG2000-phospholipid in their bilayer and where IgG1 is coupled to the distal end of PEG2000, not only drain rapidly from the interstitial spaces into the initial lymphatic system, but also accumulate efficiently among the lymph nodes draining the region when compared with non-PEG-bearing immunoliposomes where IgG is directly coupled to the phospholipid. Liposome deposition among the draining lymph nodes, however, was further enhanced dramatically following an adjacent subcutaneous injection of a pentameric IgM against the surface attached IgG molecules (IgM:IgG, 10:1) without compromising vesicle drainage from the interstitium. This is suggested to arise either as a result of formation of large immuno-aggregates within the lymphatic vessels with subsequent transport to and trapping among the regional lymph nodes and/or following IgM binding to Fc receptors of the lymph node sinus macrophages forming a platform for subsequent trapping of drained IgG-coupled liposomes. This lymph node targeting approach may be amenable for the design and surface engineering of any rapidly drained nanoparticulate system bearing peptides and proteins that can be aggregated with a desired monoclonal pentameric IgM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936719     DOI: 10.1016/j.bbamem.2007.08.033

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Post-lumpectomy intracavitary retention and lymph node targeting of (⁹⁹m)Tc-encapsulated liposomes in nude rats with breast cancer xenograft.

Authors:  Shihong Li; Beth Goins; William T Phillips; Marcela Saenz; Pamela M Otto; Ande Bao
Journal:  Breast Cancer Res Treat       Date:  2010-12-23       Impact factor: 4.872

2.  Creating functional vesicle assemblies from vesicles and nanoparticles.

Authors:  Robert J Mart; Kwan Ping Liem; Simon J Webb
Journal:  Pharm Res       Date:  2009-04-23       Impact factor: 4.200

Review 3.  Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles.

Authors:  Shuang Cai; Qiuhong Yang; Taryn R Bagby; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2011-06-25       Impact factor: 15.470

Review 4.  Harnessing nanostructured systems for improved treatment and prevention of HIV disease.

Authors:  Maya Monroe; Charles Flexner; Honggang Cui
Journal:  Bioeng Transl Med       Date:  2018-07-27

5.  Targeted lipid nanoparticle delivery of calcitriol to human monocyte-derived macrophages in vitro and in vivo: investigation of the anti-inflammatory effects of calcitriol.

Authors:  Aisha Rafique; Anders Etzerodt; Jonas H Graversen; Søren K Moestrup; Frederik Dagnæs-Hansen; Holger Jon Møller
Journal:  Int J Nanomedicine       Date:  2019-04-23

6.  Stannous colloid mixed with indocyanine green as a tracer for sentinel lymph node navigation surgery.

Authors:  Yiting Zhang; Tomoya Uehara; Taro Toyota; Ryusuke Endo; Hisahiro Matsubara; Hideki Hayashi
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

Review 7.  Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.

Authors:  Arshad Ali Khan; Jahanzeb Mudassir; Noratiqah Mohtar; Yusrida Darwis
Journal:  Int J Nanomedicine       Date:  2013-07-26

8.  Improved lymphatic targeting: effect and mechanism of synthetic borneol on lymph node uptake of 7-ethyl-10-hydroxycamptothecin nanoliposomes following subcutaneous administration.

Authors:  Tiantian Ye; Yue Wu; Lei Shang; Xueqing Deng; Shujun Wang
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.